OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) and is used in the treatment of seizures.
The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
Yesafili, received marketing authorization approval from the European Commission for the European Union
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
he company posted total income during Q2 FY24 at Rs. 12.86 crore
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Subscribe To Our Newsletter & Stay Updated
